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Summary Carboplatin clearance depends on the glomerular filtration rate (GFR), and Calvert's formula is frequently used to achieve a target
area underthe time vs concentration curve (mg ml-' min). Creatinine clearance is a substitute for GFR when creatinine values are determined
by the Jaffe method, which is being replaced by the enzymatic method. When the enzymatic method is used, the corresponding creatinine
clearance theoretically exceeds GFR, and the use of creatinine clearance as GFR in Calvert's formula results, accordingly, in overdosing of
carboplatin. In this study, we have established a model for adjusting the creatinine clearance to offset this bias based on a relationship
between creatinine values measured by the Jaffe method and by the enzymatic method: adjusted creatinine clearance (ml min-') = creatinine
clearance (ml min-1) x [serum creatinine (mg di-')]/[serum creatinine (mg dl-1) + 0.2]. Subsequently, we validated this model using the data
from 35 lung cancer patients. Estimated clearances of carboplatin with the original equation [creatinine clearance + 25] were systematically
higher than observed clearances [mean prediction error (MPE) ± standard error (s.e.) = 26 + 5%]. This positive bias was corrected by the
adjustment (MPE ± s.e. = 5 ± 4%). When the enzymatic method is used, the adjusted creatinine clearance should be used in Calvert's
formula.
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Carboplatin clearance depends on the glomerular filtration rate
(GFR), and Calvert's formula is frequently used for determination
of the dosing: dose (mg) = target AUC x [GFR (ml min-1) + 25],
where AUC denotes the areaunderthe time vs concentration curve
(mg ml-' min) (Harland et al, 1984; Calvert et al, 1989). In devel-
oping this formula, the GFR has been measured using the
[5'Cr]EDTA clearance method. However, many oncologists have
used creatinine clearance as a measure of GFR in the clinical use
ofthis formula (Green and Smith, 1990; Sessa et al, 1991; Jodrell
et al, 1992; Reyno et al, 1993; Langer et al, 1995), because
obtaining the creatinine clearance is more convenient than
measuring GFR directly. However, creatinine is both filtered by
glomeruli and secreted by renal tubules, so the creatinine clearance
theoretically exceeds GFR, thereby causing carboplatin over-
dosing (Doolan et al, 1962; Kassirer, 1971; Shemesh et al, 1985;
Levey et al, 1991). We have reported more than 20% overdosing
by replacing GFR with the creatinine clearance in this formula
(Ando et al, 1997).
At present, two methods are available for measuring creatinine
levels, the Jaffe method and the enzymatic method (Doolan et al,
1962; Fabiny and Ertingshausen, 1971; Kassirer, 1971; Larsen,
1972; Lustgarten and Wenk, 1972; Guder and Hoffmann, 1986;
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Crocker et al, 1988). The Jaffe method is based on a picrate reac-
tion with creatinine under alkaline conditions and has been widely
used for a long time with several modifications to the detailed
procedure (Doolan et al, 1962; Fabiny and Ertingshausen, 1971;
Larsen, 1972; Lustgarten and Wenk, 1972). This method is known
to overestimate the serum level ofcreatinine by 5-15% because of
a reaction with non-creatinine chromogens in serum but not in
urine (Doolan et al, 1962; Kassirer, 1971). As a result ofthis bias,
the true creatinine clearance is underestimated and can be accepted
as a useful measure ofGFR in clinical practice as this error coinci-
dentally offsets the excess of creatinine clearance over GFR
(Levey et al, 1991). On the other hand, the new enzymatic method
is more specific and ensures better interlaboratory agreement than
the traditional Jaffe method (Guder and Hoffmann, 1986; Crocker
et al, 1988). Because the enzymatic method is not influenced by
chromogens, the serum creatinine level is lower than when using
the Jaffe method, and the corresponding creatinine clearance
would be higher than GFR (Guder and Hoffmann, 1986; Crocker
et al, 1988; Weber and van Zanten, 1991; Sokoll et al, 1994).
Hence, the replacement of GFR with creatinine clearance in
Calvert's formula causes carboplatin overdosing when the enzy-
matic method is used. This would explain the overestimation of
carboplatin clearance in ourprevious study in which the enzymatic
method was used.
We have attempted to evaluate the relationship between the
creatinine levels determined using the Jaffe method and those
determined using the enzymatic method. We have thus established
a model to adjust the creatinine clearance by the enzymatic
method to be used as GFR in Calvert's formula for the accurate
prediction ofthe carboplatin clearance.
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Table 1 Patient characteristics and observed AUC
Regimena A/B/C 14/11/10
Gender Female/male 9/26
Age (years) Median 61 (34-81)
Serum creatinine (mg dl-1) Mean ± s.d. 0.8 ± 0.4
Median (range) 0.7 (0.5-2.7)
Creatinine clearance (ml min-1)b Mean ± s.d. 92 ± 29
Median (range) 91 (12-154)
Weight (kg) Median (range) 50 (41-85)
Body surface area (m2) Median (range) 1.49 (1.30-1.89)
Total dose of carboplatin (mg) Median (range) 514 (201-1162)
Observed AUC (mg ml-' min) Median (range) 5.75 (2.53-10.47)
aCarboplatin was administered alone in regimen A and B, and with innotecan in
regimen C. bCreatinine values were all determined using the enzymatic method.
AUC, area underthe concentration time curve; s.d. standard deviation.
METHODS
Relationship between the Jaffe method and the
enzymatic method
We measured creatinine levels in serum and urine of the patients
admitted to Shinshiro Municipal Hospital from November 1995 to
March 1996. Diseases of these patients included various cancers,
chronic obstructive pulmonary disease, ischaemic heart diseases,
stable diabetes and chronic renal failure. Haemolysed samples or
those from patients receiving any kind of antibiotics or vitamins
were excluded (Lustgarten andWenk, 1972; Guderand Hoffmann,
1986; Crocker et al, 1988; Weber and van Zanten, 1991). A urine
sample from 24-h urine collection was obtained in the morning
when the patient's serum sample was taken. The samples were
stored at-20°C until analysis.
The serum and urine creatinine levels were determined using
both the Jaff6 method and the enzymatic method. The kinetic Jaff6
method without deproteinization was performed with creatinine-
HR (Wako Pure Chemical Industries, Osaka) using the auto-
analyser Hitachi 747-400. The intra- and inter-day coefficient
variation (CV) of the assay was under 3% and 6% respectively.
The enzymatic method was carried out with Determiner-L CRE
(Kyowa Medex, Tokyo) using Hitachi 717. The intra- and inter-
day CV was less than 2% and 3% respectively. We developed
equations using linear regression to convert creatinine values by
the enzymatic method to those by theJaffe method. Based on these
equations, a model was developed to adjust creatinine clearance so
as to be similar to GFR.
Carboplatin pharmacokinetics
The pharmacokinetic data were available from 35 lung cancer
patients (Table 1). They were treated with three different regimens
including carboplatin (Table 2). Carboplatin was infused as
monotherapy with the target AUC (mg ml-1 min) of seven for
untreated or five forpreviously treated patients in regimens A or B
(Calvert et al, 1989). No antineoplastic treatment was allowed
during the 4 weeks before entry for previously treated patients (3
months for cisplatin-containing regimen) (Daugaard et al, 1988).
In regimen C, previously untreated patients received irinotecan at
a dose ranging from 40 to 60 mg m-2 followed by carboplatin.
Creatinine clearance from 24-h urine collection was measured
three times in regimens A and B or two times in regimen C, and
Table 2 Chemotherapy regimens
Regimen A
Dose (mg) Target AUC x [creatinine clearance (ml min-1) + 25]
Infusion time 60 min
Sampling 0, 0.25, 0.5, 1, 2, 4, 8 h
Regimen B
Dose (mg) Target AUC x [0.76 x creatinine clearance (ml min-') + 15]
Infusion time 60 min
Sampling 0, 0.25, 0.5,1,1.5, 2, 4, 6, 8,12, 24 h
Regimen C
Dose (mg m-2) 300
Infusion time 90 min after irinotecan infusion
Sampling 0, 0.25, 0.5, 1, 2.5, 4, 6.5, 22.5 h
AUC, area under the concentration vs time curve (mg mI-1 min).
the average value in each patient was used. Creatinine clearance
was expressed as the absolute value in ml min-' without correction
for the body surface area.
Creatinine clearance (ml min-')
- [urine volume (ml min-')] x urine creatinine (mg dl-')
serum creatinine (mg dl-') (1)
Blood samples were taken in a tube coated with a coagulation
accelerant (Insepack, Sekisui Medical, Osaka) for pharmaco-
kinetic analysis of carboplatin in regimens A and B, and the
serum was immediately separated by centrifugation. Ultrafiltered
serum was obtained using a Millipore Ultrafree-C3 filter unit
(UFC3LGC0O, Japan Millipore, Tokyo). In regimen C, plasma
was obtained in heparinized tubes and was ultrafiltered with
Amicon MPS micropartition system with YMT membranes
(Grace Japan KK, Amicon, Tokyo). According to our data, the
absolute difference in free platinum levels between the two proce-
dures was 3.5 ± 0.8% (mean ± standard error, n = 13). The ultra-
filtered samples were stored at -20°C until analysis. All studies
were approved by each institutional ethics committee, and written
informed consent was obtained from all patients.
The ultrafiltered platinum level was measured by flameless
atomic absorption spectrometry (LeRoy et al, 1977). The lower
limit of detection was 25 ng ml'. The intra- and interassay CV
was 2.6% and 4.1% respectively. The carboplatin level was calcu-
lated based on the molar ratio of platinum-carboplatin. Observed
AUC was calculated by the trapezoidal method with extrapolation
to infinity using PCNONLIN (version 4.0, Scientific Consulting,
Apex, NC, USA). Estimated and observed clearances were calcu-
lated as follows:
Estimated clearance (ml min-1) =
creatinine clearance (ml min-') + 25
Observed clearance (ml min-') =
dose (mg)
observed AUC (mg ml-1 min)
All creatinine values had been determined by the enzymatic
method. We recalculated the corresponding creatinine clearance in
individual patients using the developed model. The accuracy ofthe
clearance estimation was evaluated with the mean prediction error,
its standard error (MPE ± s.e.) and the root mean squared error
(RMSE) (Sheiner and Beal, 1981).
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Table 3 Linear regression analysis of creatinine levels determined by the
Jaffe method and the enzymatic method
Sample
Serum Serum Urine
n 85 73 32
Range examineda (mg dl-1) 0.4-8.7 0.4-1.7 28.8-159.5
Median 0.9 0.8 57.35
Slopeb 0.99 0.92 1.02
95% Confidence interval 0.98-1.01 0.84-0.99 1.00-1.04
Interceptb 0.18 0.25 - 0.04
95% Confidence interval 0.15-0.22 0.18-0.32 - 1.57-1.49
r 1.00 0.94 1.00
aThe creatinine values were all determined by the enzymatic method.
bThe values determined by the Jaffe method and those determined by the
enzymatic method were dependent and independent variables respectively.
MPE = I x I (estimated - observed) (ml min-')
1
I ; x (estimated - observed x 100) (%)
observed
RMSE = [1 x I (estimated -observed)2]2 (ml min-1) n
= [ X esimated -observed
[n x£( observed x 100)21 (%)
RESULTS
The linear regression analysis for serum creatinine levels between
the Jaffe and enzymatic methods showed a slope of 0.99 and an
intercept of 0.18, which was significantly different from zero
(Table 3 and Figure 1). This implied that the values determined
by the Jaffe method consistently exceeded those obtained by
the enzymatic method for all creatinine levels investigated. To
confirm that this relationship can be applied for the relevant levels
to each dosing, we examined samples containing < 1.7 mg dl-1 as
measured by the enzymatic method. The results were essentially
the same (Table 3). Thus, when the enzymatic method was used to
measure creatinine levels, serum creatinine in the denominator of
the equation for creatinine clearance (eqn 1) should be replacedby
serum creatinine + 0.2. On the other hand, good agreement was
found in the urine creatinine levels by the two methods, and no
modification was needed in the equation (Table 3 and Figure 1).
Therefore, when creatinine levels were measured by the enzymatic
method, GFR was estimated by adjusting the clearance as follows:
Adjusted creatinine clearance (ml min-') =
[urine volume (ml min-1)] x urine creatinine (mg dl-[)
serum creatinine (mg dl-') + 0.2
= creatinine clearance (ml min-') x
serum creatinine (mg dl-1)
serum creatinine (mg dl -') + 0.2
When the creatinine clearance was calculated with the values
analysed by the enzymatic method and used in Calvert's formula,
the estimated carboplatin clearance was positively biased and
imprecise. After adjustment using the above model, this bias was
significantly decreased (P < 0.001 by paired t-test; Table 4 and
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Figure 1 Relationship between creatinine values analysed by the enzymatic
method and by the Jaff6 method in 85 serum (A) or 32 urine (B) samples.
Lines denote the lines of identity
Figure 2). The precision expressed as RMSE was also improved
(Table 4).
DISCUSSION
The bias and precision of the carboplatin clearance estimation
were improved by adjusting the creatinine clearance calculated
with the values measured by the enzymatic method. This result
confirmed our hypothesis that the use of the enzymatic method
for serum creatinine determination overestimates carboplatin
clearance when creatinine clearance is used as a substitute for
GFR in Calvert's formula.
Recently, Chatelut et al (1995) proposed an alternative formula
to calculate carboplatin clearance using the non-linear mixed-
effect model (NONMEM), which included variables such as age,
gender, weight and serum creatinine measured with an enzymatic
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Table 4 Observed and estimated clearances of carboplatin
Mean ± s.d. MPE ± s.e. RMSE
Observed (ml min-1) 97.5 ± 32.9
Estimated
Original (ml min-') 117.3 ± 29.1 19.8 ± 4.2 31.3
(%) (26 ± 5) (37)
Adjusted (ml min-1) 96.5 ± 22.6 - 1.0 ± 4.1 24.0
(%) (5 ±4) (23)
s.d., Standard deviation; MPE ± s.e., mean prediction error ± standard error;
RMSE, root mean square error.
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Figure 2 Comparisons of the observed carboplatin clearances and those
estimated before (A) or after (B) adjustment of creatinine clearance. Lines
denote the lines of identity
method (Chatelut et at, 1997). This model is beneficial when
accurate measurement of GFR or creatinine clearance is difficult.
However, in our study population, the Chatelut formula overesti-
mated carboplatin clearance by 37±+5 ml min-1 (42±5%SS,
MPE ± s.e.). There might be an ethnic difference in the utility
ofthe Chatelut formula or a further as yet unestablished difference
in the method ofcreatinine measurement.
This report recommends discontinuation ofthe Jaffe method for
creatinine measurement, as it is readily influenced by non-creati-
nine chromogens and shows more interlaboratory variation
(Doolan et al, 1962; Kassirer, 1971; Guder and Hoffmann, 1986).
Instead, we suggest that creatinine levels should be measured by
the enzymatic method while adjusting the creatinine clearance.
This adjustment would lead to safer individualized dosing of
carboplatin using Calvert's formula.
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